A multicentre study found that darifenacin significantly improved median warning time by 4.3 minutes in patients with overactive bladder syndrome, leading to a 22.5% increase in mean warning time.
The Organ Transplantation Research Foundation (ROTRF) has received continued funding from Roche, a global healthcare leader. The foundation supports groundbreaking research in transplantation, aiming to improve the lives of people with transplanted organs.
The CHARM Programme demonstrates clear benefits of Atacand in treating heart failure, reducing risk by 23% in ACE-inhibitor intolerant patients and 15% in those taking conventional therapy. Additionally, Atacand shows a trend towards reduced cardiovascular death and hospitalizations in patients with preserved left ventricular function.
A clinical trial found that early treatment with Atacand significantly reduced 12-month mortality and vascular events in patients with acute ischaemic stroke. The study also showed a comparable tolerability profile to placebo.
The study reveals that renal amyloidosis is associated with a poor prognosis in patients with Familial Mediterranean Fever. AA amyloidosis is a chronic and fatal disease marked by the deposit of amyloid fibrils in the kidney, leading to organ dysfunction and death.
The XPERT TM study shows Xyzal significantly improved symptoms and quality of life for patients with persistent allergic rhinitis. Long-term treatment reduced co-morbidity, lost productivity, and economic savings.
New data from the Roche Organ Transplantation Research Fund challenge the idea that potent immunosuppressants increase cancer risk. People receiving CellCept are less likely to develop lymphoma or post-transplant lymphoproliferative disease, with a lower risk of malignant lymphoma compared to conventional immunosuppressive treatment.
The GELA study reveals that MabThera plus CHOP improves three-year event-free survival by 18% and overall survival by 11%, with no increased toxicity. This breakthrough treatment offers a potential cure for aggressive NHL, which affects 55% of the 1.5 million people worldwide suffering from non-Hodgkin's lymphoma.
The KEPPRA international Phase IV SKATE study achieved a significant reduction in partial seizures in 49% of patients, with a seizure freedom rate of 17.2%. The study showed favourable efficacy across various subtypes of partial seizures.
The study finds that adding Keppra to standard therapy can lead to seizure freedom in refractory patients with a moderate increase in costs. This results in significant healthcare savings, making it a cost-effective alternative.
The SPORTIF III study demonstrates Exanta's efficacy in preventing stroke and systemic embolic events, with a 41% reduced risk of major bleeding events compared to warfarin. The fixed-dose oral medication offers a convenient alternative to traditional treatment, eliminating the need for coagulation monitoring and dietary restrictions.
A recent community-based clinical trial found that Keppra significantly reduced partial seizures in nearly 80% of elderly patients, aged 65 and older, with a median overall reduction in seizure frequency of 80.1%. The medication was well-tolerated, with a low incidence of side effects.
A review of 176 patients found that the addition of Keppra led to complete seizure control in 22.3% of patients who had at least 12 months of treatment, with some also experiencing reduction or discontinuation of other anti-epileptic drugs.
A Phase III study of Raptiva found that 27% of patients experienced a 75% or greater Psoriasis Area and Severity Index (PASI) score improvement after 12 weeks of therapy. Patients also showed rapid onset of effects on quality of life measurements, providing further support for Raptiva as a potential treatment option.
A study of over 339 patients found that 77% of those continuing Raptiva therapy had a PASI 50 score and 51% achieved a PASI 75 score. Long-term treatment showed improved response rates, with 22% achieving a 90% or greater improvement in their PSASI score.
A new study finds Keppra alleviates severe nerve pain in cancer patients by reducing VAS scores to 0-3 within 3-14 days, with a significant decrease in opioid use. The medication was well-tolerated and showed potential therapeutic benefits for further investigation.
UCB's pharma sector announces a new antiepileptic drug candidate, ucb 34714, which demonstrates higher efficacy than existing levetiracetam in reducing epileptiform activity and seizure severity. The compound also shows tolerability and disease-modifying properties, supporting its potential for improving epilepsy therapy.
A study found that Keppra, when used in combination with conventional treatments, provided significant pain relief for multiple sclerosis (MS) patients. Over half of the participants showed marked improvement and continued treatment with Keppra.
A community study of 400 patients with various pain types found that Keppra was well-tolerated and provided significant pain relief. The medication was effective in treating a range of conditions, including migraine headaches, nerve pain, and diabetic pain.
A large-scale study confirms KEPPRA's efficacy in reducing seizure frequency and achieving seizure freedom in patients with refractory epilepsy. The study analyzed data from 1,422 patients over a 54-month period, showing sustained antiepileptic benefits without tolerance developing.
A 12-week study shows candesartan cilexetil significantly reduces headache days and sick leave in patients with migraines. The medication's benefits are associated with good tolerability, making it an exciting alternative to current therapies.
In the Phase II study, natalizumab demonstrated higher rates of clinical remission compared to placebo at multiple time points. The highest rate of remission was observed in the dual 3 mg/kg dose group, with a maximal response of 71%.
A Phase II study published in NEJM found that natalizumab significantly reduced new gadolinium-enhancing lesions by up to 93% and the number of patients experiencing relapses by 50%. The treatment was well-tolerated, with common adverse events including infection and rash.
Results from THRIVE III study demonstrate that oral EXANTA is effective in preventing recurrence of VTE events by 84% compared to placebo. The data also show no significant increase in total bleeding events for EXANTA.
A recent study using the Environmental Exposure Unit (EEU) technology compared the efficacy of Xyzal and NeoClarityn in controlling seasonal allergic rhinitis symptoms. The results showed that Xyzal was more effective than NeoClarityn in relieving major symptoms, with a faster onset of action and longer duration of relief.
New data confirm KEPPRA's sustained antiepileptic effect over 7.13 years, with a high retention rate of 54.3%. The incidence of adverse events is similar to previous studies, ensuring the safety and tolerability profile for KEPPRA.
A new study shows that CellCept substitution of cyclosporine reverses renal toxicity, improving the life span of transplanted kidneys. 58% of patients on CellCept therapy had a reversal or stabilisation of their kidney function compared to 32% on cyclosporine.
The AT1-receptor blocker Atacand significantly reduces non-fatal strokes in elderly patients with mild hypertension while maintaining cognitive function. Lowering blood pressure also shows no significant increase in cognitive decline or dementia risk.
Nearly a third of surveyed glaucoma patients reported difficulties with taking multiple medications, citing missed dosing and inadequate waiting periods. Physicians advocate for more patient education and convenient treatments to improve compliance and vision outcomes.
A new study published in the New England Journal of Medicine shows that cardiac resynchronisation therapy systems improved NYHA functional class, six-minute walk distance, and quality of life for patients with moderate-to-severe heart failure. The treatment also reduced hospitalisations by 50% and hospital days by 77%.
A total of 825 patients with primary open-angle glaucoma or ocular hypertension showed significant improvements in intraocular pressure after switching to XALATAN. The study found that 83% of patients experienced a reduction in IOP due to inadequate control, and 90% of those who switched due to adverse events maintained IOP control.
A study found XALACOM to be more effective than Cosopt in reducing intraocular pressure by 1.00 mmHg, with fewer reported eye pain and irritation. XALACOM was also well-tolerated systemically, with no taste disturbances reported.
A five-year study demonstrated Xalatan's efficacy in managing open-angle glaucoma by reducing intraocular pressure (IOP) sustainably. The treatment was well-tolerated, controlling IOP without surgery in 72% of patients.
A recent study found that CellCept therapy can effectively reverse kidney damage and improve graft survival in patients with chronic kidney function decline. The results showed a significant increase in kidney function reversal or stabilization in patients treated with CellCept compared to those on cyclosporine.
Despite being a significant advancement in Parkinson's disease treatment, only 7% of eligible patients in G5 European countries have received deep brain stimulation therapy. Inconsistent funding support and low awareness among general practitioners are major barriers to access.
A new combination of MabThera and standard chemotherapy has shown a significant increase in overall survival rate and complete remission rates in patients with aggressive non-Hodgkin's lymphoma. This treatment offers hope for improved outcomes in this increasingly common form of blood cancer.
A global white paper on bacterial resistance in respiratory tract infections calls for concerted international action to tackle the growing threat of antibiotic-resistant bacteria. The initiative aims to implement robust surveillance, education, and patient involvement to control resistance.
Exanta shows comparable efficacy to warfarin in preventing stroke in patients with atrial fibrillation, with the added benefit of no dose titration or routine coagulation monitoring. The THRIVE programme also highlights Exanta's promise in treating venous thromboembolism.
A new global survey found that 91% of physicians prescribe MabThera for NHL, with 62% citing proven efficacy in combination with chemotherapy. Non-Hodgkin's Lymphoma affects 1.5 million people worldwide, with Roche's MabThera showing improved survival rates when combined with conventional chemotherapy.
Researchers found that the MabThera plus CHOP combination significantly improves overall survival for patients with aggressive non-Hodgkin's lymphoma, with a 70% survival rate after 26 months. The treatment is also effective in treating indolent NHL, with up to 55% of patients remaining in remission at four years.
The ACCESS study confirms that Atacand improves outcomes for patients with acute ischaemic stroke and high blood pressure. Early treatment with Atacand reduces the risk of total mortality, cerebral complications, and cardiovascular complications by 47.5 percent.
A new study found that Topamax significantly reduced the severity of manic symptoms in patients with bipolar disorder, with 70% experiencing improvement. The medication was well-tolerated, with no significant weight gain and fewer side effects compared to traditional treatments.
The OPTIMA study shows that low-dose budesonide alone reduces the risk of severe asthma exacerbations and poorly controlled days by half in previously untreated patients. Adding formoterol improves symptom control and reduces exacerbations in both previously untreated and corticosteroid-treated patients.
A recent survey found that patients with breast cancer in Europe have limited knowledge about innovative treatments like Herceptin and HER2 diagnostic testing. This lack of awareness can lead to women not making informed decisions about their treatment, highlighting the need for improved education and communication.
The HERA (HERceptin Adjuvant) Study aims to determine if earlier use of Herceptin increases disease-free survival for women with early breast cancer. The trial will recruit over 3000 patients across 600 trial sites globally.
The TALENT trial assesses Tarceva's value in NSCLC treatment, showing promising anti-tumor activity. Additionally, a Phase Ib study evaluates Tarceva's feasibility in combination with chemotherapy for advanced breast cancer.
Research found that patients taking Reminyl experienced reduced time spent supervising and assisting daily activities, while caregivers reported a decrease in stress and an increase in independence. The medication may delay institutionalization and have a positive economic impact.
The International Lipid Information Bureau (ILIB) emphasizes the importance of statins in lowering cholesterol and preventing coronary heart disease. Landmark clinical trials have shown that statins prevent CHD, heart attacks, revascularization, and strokes.
A new international survey reveals that people are largely unaware of their cholesterol risk, with 13% believing they're at high risk for heart disease. Despite having multiple risk factors, many individuals incorrectly assess their level of risk, highlighting the need for education and awareness campaigns.
Exanta demonstrated improved safety and tolerability compared to warfarin in treating patients with medium to high risk for stroke and systemic embolism. The phase III SPORTIF programme enrolled over 6,200 patients and showed promising results. Exanta is being investigated as a simpler alternative to warfarin treatment.